U.S. Markets closed

Momenta Pharmaceuticals, Inc. (MNTA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.80-0.45 (-2.61%)
At close: 4:00PM EDT

16.80 0.00 (0.00%)
After hours: 4:22PM EDT

People also watch
Full screen
Previous Close17.25
Bid16.75 x 100
Ask17.75 x 200
Day's Range16.65 - 17.35
52 Week Range10.50 - 19.90
Avg. Volume824,117
Market Cap1.25B
PE Ratio (TTM)-40.29
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • InPlay from Briefing.com
    Briefing.com29 minutes ago

    InPlay from Briefing.com

    InPlay from Briefing.com

  • Reuters1 hour ago

    U.S. jury sides with Amphastar over Momenta in drug patent trial

    A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox. The verdict by the jury in Boston came in a lawsuit by Cambridge, Massachusetts-based biotechnology company Momenta and its partner, Novartis AG's Sandoz unit, that sought nearly $940 million in damages. The jury found that while Rancho Cucamonga, California-based Amphastar had infringed Momenta's patent, it was invalid and unenforceable.

  • American City Business Journals1 hour ago

    ​Jury nixes Momenta patent case that sought $938M in damages

    A federal jury has rejected a $938 million lawsuit filed by Momenta Pharmaceuticals that accused a California drugmaker of infringing its patent covering a generic blood-thinner. According to court records, the jury ruled Friday that while Amphastar Pharmaceuticals (AMPH) infringed Momenta’s (MNTA) patent for testing the quality of batches of the drug, the patent was invalid. Momenta and its partner, Novartis unit Sandoz, had sought $938 million in damages in the trial, which began July 11.